Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Sonoma Pharmaceuticals, Inc.SNOA · Entity 8177 | Chief Financial Officer | December 29, 2022 | December 30, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Sonoma Pharmaceuticals, Inc.
Report date December 29, 2022 · Filed December 30, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.08 · Expires 2032-12-29 | Direct | 14,753 |
Reported balance
After 2022-12-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-12-29 · Grant · Acquired 9,753 · Balance 14,753 F2: The options were awarded and granted to Mr. White for services performed as part of the Company's annual grant of stock options. F1: The options vest one third each on 12/29/2023, 12/29/2024 and 12/29/2025, or upon change of control. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest one third each on 12/29/2023, 12/29/2024 and 12/29/2025, or upon change of control.
F2: The options were awarded and granted to Mr. White for services performed as part of the Company's annual grant of stock options.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 29, 2022 Filed Dec 30, 2022 22:02 UTC | Sonoma Pharmaceuticals, Inc. SNOA · Entity 8177 | GrantStock option (right to buy) · Derivative | 9,753 | Not disclosed Strike: $1.08 | Not disclosed |
DisclosureSEC source: 0001683168-22-008722 · ownership.xml · derivative · entry 1 White Chad Norman · CIK 0001949607 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,753 Underlying: Common Stock · 9,753 shares Expires 2032-12-29 F2 · price: The options were awarded and granted to Mr. White for services performed as part of the Company's annual grant of stock options. F1 · derivative.exercise_date: The options vest one third each on 12/29/2023, 12/29/2024 and 12/29/2025, or upon change of control. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.